Diffuse melanosis cutis (DMC) is a rare presentation ofmetastatic melanoma associated with a particularlyguarded prognosis. The advent of target therapies hastransformed the landscape of management in patients withmetastatic melanoma, however it is yet to be determinedwhether this includes patients with a particularly poor prog-nosis such as those with DMC. We report a case of a 35 yearold male with BRAFV600Emetastatic melanoma treated withvemurafenib (as well as Ipilimumab and whole brain radio-therapy), who is alive, 25 months beyond the onset of hisDMC. This is significantly longer than the reported meansurvival of four months, further highlighting the promisingsurvival advantage of targeted therapies when compared toconventional chemotherapeutic regimens.
|Number of pages||1|
|Journal||Australasian Journal of Dermatology|
|Issue number||Supplement s1|
|Publication status||Published - May 2014|